title: Use of postmenopausal hormone therapy since the Women's Health Initiative findings.
abstract: OBJECTIVE
  To assess how use of postmenopausal hormone therapy (PHT) has changed since the Women's Health Initiative (WHI) trial was halted early due to an excess risk of stroke and other adverse outcomes. To estimate whether use of alternative drugs to treat menopausal symptoms (e.g., selective serotonin reuptake inhibitors [SSRIs], soy) has increased.
  
  
  METHODS
  Women were interviewed in the Slone Survey, a random-digit-dial (RDD) survey of current medication use in a representative national sample. Information was obtained on PHT including dose, route, and reason for use, and on use of alternative drugs to treat menopausal symptoms. There were 3853 women aged >or=50 years, interviewed from 1/2001 to 6/2004.
  
  
  RESULTS
  The average weekly prevalence of PHT declined 57%, from 28% in the first half of 2002 to 12% in the first half of 2004. Use declined for conjugated estrogens (CE) and for other estrogens, taken either alone or with progestin. The decrease exceeded 50% in most strata of age, race, education, and region. The proportion of PHT users taking 0.3 mg CE did not change. Comparing prevalence in 2004 with prevalence in 2002, there was no material increase in use of black cohosh (2.0% in 2004) or soy (2.0%) and use of SSRIs was somewhat lower (8.9%).
  
  
  CONCLUSIONS
  These population-based usage data demonstrate a large decline in PHT use among women of postmenopausal age. The proportion of CE users taking lower doses has not increased. On a population basis, millions fewer women are using PHT in 2004 than before the WHI results were published, but there has been no appreciable increase in use of alternative therapies for menopausal symptoms over the same period.
authors.affiliation: Slone Epidemiology Center, Boston University, Boston, MA 02215, USA. jkelly@slone.bu.edu
authors.forename: Judith Parsells
authors.initials: JP
authors.lastname: Kelly
authors.forename: David W
authors.initials: DW
authors.lastname: Kaufman
authors.forename: Lynn
authors.initials: L
authors.lastname: Rosenberg
authors.forename: Katherine
authors.initials: K
authors.lastname: Kelley
authors.forename: Saskia G
authors.initials: SG
authors.lastname: Cooper
authors.forename: Allen A
authors.initials: AA
authors.lastname: Mitchell
mesh_terms: D000529:Complementary Therapies / Q000706:statistics & numerical data / Q000639:trends; D003625:Data Collection; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000706:statistics & numerical data / Q000639:trends*; D005260:Female; D029001:Herbal Medicine / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D045730:Soy Foods / Q000706:statistics & numerical data; D014481:United States; D016387:Women's Health
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors